Market capitalization | $174.83m |
Enterprise Value | $125.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.71 |
P/S ratio (TTM) P/S ratio | 16.37 |
P/B ratio (TTM) P/B ratio | 2.89 |
Revenue growth (TTM) Revenue growth | 48.37% |
Revenue (TTM) Revenue | $10.68m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
4 Analysts have issued a Profound Medical Corp forecast:
4 Analysts have issued a Profound Medical Corp forecast:
Dec '24 |
+/-
%
|
||
Revenue | 11 11 |
48%
48%
|
|
Gross Profit | 7.74 7.74 |
77%
77%
|
|
EBITDA | -32 -32 |
17%
17%
|
EBIT (Operating Income) EBIT | -33 -33 |
16%
16%
|
Net Profit | -28 -28 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, CA.
Head office | Canada |
CEO | Arun Menawat |
Employees | 142 |
Founded | 2008 |
Website | www.profoundmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.